Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis

Rheumatology (Oxford). 2025 Jun 1;64(6):4075-4077. doi: 10.1093/rheumatology/keaf077.

Fredrik N Albach¹, Ioanna Minopoulou¹, Artur Wilhelm^{1

2}, Robert Biesen¹, Arnd Kleyer¹, Edgar Wiebe¹, Anja Fleischmann¹, Mareike Frick³, Frederik Damm³, Julia Gogolok³, Sebastian Serve³, Benjamin Nick Locher³, Dominic Borie⁴, Vincent Casteleyn¹, Elise Siegert^{1

2}, Thomas Dörner^{1

2}, Tobias Alexander^{1

2}, Christian Furth⁵, Jan Zernicke¹, Kamran Movassaghi³, Marie Luise Hütter-Krönke⁶, Eva Schrezenmeier^{2

7}, Udo Schneider¹, Lars Bullinger^{3

8}, Gerhard Krönke^{1

2

9

10}, Olaf Penack³, David Simon^{1

2

9

10}

¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.
³ Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
⁴ Kyverna Therapeutics, Emeryville, CA, USA.
⁵ Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁶ Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany.
⁷ Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁸ Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
⁹ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
¹⁰ Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

No abstract available

Grants and funding